CMS has advised Scope Fluidics on an agreement with Bio-Rad Laboratories under which it received USD 30m in settlement of conditional payments related to the sale of the Curiosity Diagnostics SPV.
Scope Fluidics is a Polish biotechnology company specialising in the design and development of innovative projects based on microfluidic technologies in medical diagnostics and healthcare.
In 2022, Scope Fluidics sold Curiosity Diagnostics, which develops innovative technology solutions for the medical diagnostic and healthcare markets, to Bio-Rad Laboratories, a leading US med-tech company, along with its innovative PCR|One system.
Scope Fluidics received USD 100m as part of the first phase of the transaction, a record amount in the history of the Polish life science market. This new agreement increases the value of the transaction by an additional USD 30m, which Scope Fluidics received in one payment and unconditionally, in lieu of conditional payments originally scheduled to be paid over the next three years. This transaction marks another milestone in the development of the Polish biotechnology sector.
Scope Fluidics was advised by Rafał Morek and Jan Markiewicz (Dispute Resolution).
